Drug Type Universal CAR-T |
Synonyms TAA06 |
Target |
Action inhibitors |
Mechanism CD276 inhibitors(CD276 antigen inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States), Rare Pediatric Disease (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neuroblastoma recurrent | Phase 1 | China | 30 Dec 2022 | |
Refractory Neuroblastoma | Phase 1 | China | 30 Dec 2022 | |
Advanced Malignant Solid Neoplasm | Phase 1 | China | 01 Jun 2021 | |
Colorectal Cancer | Phase 1 | China | 01 Jun 2021 | |
Lung Cancer | Phase 1 | China | 01 Jun 2021 | |
Melanoma | Phase 1 | China | 01 Jun 2021 | |
CD276 Positive Solid Tumors | Phase 1 | - | 14 May 2021 | |
Neuroblastoma | Phase 1 | - | 14 May 2021 | |
Osteosarcoma | Phase 1 | - | 14 May 2021 | |
Stomach Cancer | Phase 1 | - | 14 May 2021 |